GlassScriptPhysician profile
William H Heaton
NPI 1710049689
$6,625.64
in general payments reported to CMS, 2019-2025
34 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $766 · 2021: $898 · 2022: $1,913 · 2023: $807 · 2024: $775 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,578.81 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Merck Sharp & Dohme LLC | $849.97 | 2021-2025 | Verquvo |
| Pfizer INC. | $474.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $470.46 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $428.18 | 2019-2024 | Farxiga |
| Amgen INC. | $427.52 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $350.92 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $331.11 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $231.86 | 2019-2023 | Xarelto |
| Lundbeck LLC | $163.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.45 | 2019-2022 | |
| Abiomed | $117.71 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.05 | 2021-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $100.03 | 2023-2025 | |
| Medtronic Vascular, INC. | $90.00 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $86.11 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $80.98 | 2019-2021 | |
| Braemar Manufacturing, LLC | $71.13 | 2019 | |
| Novo Nordisk INC | $69.35 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Shockwave Medical, INC | $60.14 | 2023-2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lexicon Pharmaceuticals, INC. | $52.41 | 2023 | Inpefa |
| Abbott Laboratories | $44.37 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $42.77 | 2023 | Optimizer |
| Irhythm Technologies, INC. | $38.13 | 2021-2023 | Zio Xt Patch |
| Actelion Pharmaceuticals US, INC. | $31.75 | 2019-2020 | |
| Chiesi USA, INC. | $31.12 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $26.23 | 2024 | Arcalyst |
| Philips North America LLC | $22.76 | 2020 | |
| Nuwellis, INC. | $20.45 | 2019 | |
| Biocompatibles, INC. | $17.39 | 2019 | |
| Terumo Medical Corporation | $15.57 | 2019 | |
| Scpharmaceuticals INC. | $15.02 | 2024 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Heaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.